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ABSTRACT 
Interferon gamma (IFNγ) is a strong inhibitor of 
osteoclast differentiation and activity. However, its role 
in osteoblastogenesis has not been carefully examined. 
Using microarray expression analysis, we found that 
several IFNγ inducible genes were upregulated during 
early phases of osteoblast differentiation of human 
mesenchymal stem cells (hMSC). We therefore 
hypothesized that IFNγ may play a role in this process. 
We first observed a strong and transient increase in 
IFNγ production following hMSC induction to 
differentiate into osteoblasts. We next blocked this 
endogenous production using a knockdown approach 
with siRNA and observed a strong inhibition of hMSC 
differentiation into osteoblasts with a concomitant 
decrease in Runx2, a factor indispensable for osteoblast 
development. Additionally, exogenous addition of IFNγ 
accelerated hMSC differentiation into osteoblasts in a 
dose dependent manner and induced higher levels of 
Runx2 expression during the early phase of 
differentiation. We next examined IFNγ signaling in 
vivo in IFNγ receptor-1 knock-out (IFNγR1
-/-) mice. 
Compared to their wild-type littermates, IFNγR1
-/- mice 
exhibited a reduction in bone mineral density. As in the 
in vitro experiments, MSC obtained from IFNγR1
-/- 
mice showed a lower capacity to differentiate into 
osteoblasts. In summary, we demonstrate that the 
presence of IFNγ plays an important role during the 
commitment of MSC into the osteoblast lineage both in 
vitro and in vivo, and that this process can be 
accelerated by exogenous addition of IFNγ. These data 
therefore support a new role for IFNγ as an autocrine 
regulator of hMSC differentiation and as a potential 
new target of bone forming cells in vivo. 
 
 
 
 
 
INTRODUCTION 
 
Maintenance of skeletal integrity is a complex 
phenomenon characterized by timely regulation 
between bone formation and bone resorption [1]. 
Osteoblast formation occurs within the bone 
marrow by differentiation of pluripotent 
mesenchymal stem cells (MSC) [2-4]. 
Regulation of osteoblastogenesis is critical in the 
acquisition and maintenance of bone mass 
throughout life [1,2,4]. MSC obtained from the 
bone marrow and exposed to ascorbic acid in 
vitro produce a collagenous extracellular matrix 
  Stem Cells Express, published online December 18, 2008; doi:10.1634/stemcells.2008-0886
  Copyright © 2008 AlphaMed Press
 
a
t
 
M
C
G
I
L
L
 
U
N
I
V
E
R
S
I
T
Y
 
L
I
B
R
A
R
Y
 
o
n
 
F
e
b
r
u
a
r
y
 
1
6
,
 
2
0
0
9
 
w
w
w
.
S
t
e
m
C
e
l
l
s
.
c
o
m
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
  
 
  2
and express specific genes associated with the 
osteoblastic phenotypes such as alkaline 
phosphatase (ALP), osteopontin (OPN) and 
osteocalcin (OCN) [3]. The transcription factors 
involved in the process of differentiation of MSC 
into osteoblasts are a subject of intense research 
since their identification could provide us with 
potential targets for bone formation. Microarray 
studies of osteoblast differentiation in mouse and 
human models in vitro have identified novel 
transcription factors that may be important in the 
establishment and maintenance of differentiation 
[5]. Most models are based on temporal changes 
post-induction of MSC that included a 
proliferative phase (wk 1), a collagen matrix 
deposition phase (wk 2), and a mineralization 
phase (wk 3) [6].  
 
In this study, we initially used human MSC 
(hMSC) that display a stable phenotype, remain 
monolayer  in vitro, and can be induced to 
differentiate into adipocytes, chondrocytes, or 
osteoblasts [3]. We performed a functional 
analysis of gene expression changes when hMSC 
are induced to differentiate into osteoblasts. Our 
data indicated that several IFNγ inducible genes 
were expressed transiently during the 
proliferative phase by hMSC undergoing 
osteoblastic differentiation in vitro. Considering 
that there is a known interplay between 
interferon and bone cells, mostly with the 
osteoclast lineage [1,7], and that the role of IFNγ 
in osteoblast differentiation and function remains 
unknown, we assessed the role of IFNγ in 
osteoblastogenesis both in vitro and in vivo. 
 
In this study we looked at IFNγ production when 
hMSC were induced to differentiate into 
osteoblasts and at the consequences of disrupting 
IFNγ production by siRNA in hMSC prior to 
their commitment to osteoblastogenesis. We also 
examined the effect of exogenous addition of 
IFNγ to cultured cells as well as the expression 
of transcription factors required in osteoblast 
differentiation [8,9]. Finally, we tested whether, 
as in our in vitro experiments, absence of IFNγ 
signaling affects osteoblastogenesis in vivo. Our 
data indicate that IFNγ plays an important role in 
hMSC commitment to osteoblastogenesis both in 
vitro and in vivo. 
 
MATERIALS AND METHODS 
 
Osteogenic Differentiation of hMSC in vitro 
The induction of osteogenic differentiation of 
hMSC was described previously [3]. Briefly, 
hMSC (BioWhittaker, Walkersville, MD, USA) 
were plated at a density of 5 x 10
5 cells per well 
in 150 cm
2 dishes containing mesenchymal stem 
cell growth medium (GM) (BioWhittaker, 
Walkersville, MD, USA) with 10% fetal calf 
serum (FCS) and incubated at 37
oC. After the 
cells reached 60% confluence, media was 
replaced with either GM or osteoblastogenesis 
induction medium (OM) (prepared with 
MSCGM, 10% FCS, 0.2mM dexamethasone, 10 
mmol/L  β glycerol phosphate and 50μg/mL 
ascorbic acid) for 21 days. Media was changed 
every three days. Media obtained at the 
beginning of the 1st, 2nd and 3rd wk of 
differentiation as well as conditioned media were 
collected for measurement of IFNγ. 
Concentrations of IFNγ in the conditioned media 
were measured from both GM and OM treated 
cells using Human NT-4 DuoSet ELISA 
Development Kit (R&D Systems, Minneapolis, 
MI, USA). 
 
cDNA Microarray Analysis of hMSC 
Total RNA was extracted from hMSC treated 
with either growth or osteogenic medium after 
the 1st and 3rd wk of differentiation using an 
Easy-Kit mini prep (Qiagen, Valencia, CA, 
USA). Generation of cDNA, fluorescent 
labeling, hybridization to the gene chip and data 
analysis were performed by the Genomics 
Laboratory at McGill University as previously 
described [10]. We examined 12,000 human 
genes and expressed sequences tags (ESTs) on 
the array Human Genome U95A (Affymetrix, 
Inc. Santa Clara, CA, USA) and analyzed the 
results using the MicroDB™ Software 
(Affymetrix, Inc. Santa Clara, CA, USA). 
Expression values of the differentiated and non-
differentiated hMSC were compared using 
Student’s t test. Genes with significant changes 
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were then grouped depending on their known 
function. The biological function of each gene 
product was obtained from literature searches in 
medical databases. This experiment was repeated 
twice and significant changes in gene expression 
determined by the method of biological 
duplicates as previously described [11,12]. 
 
Treatment of hMSC with IFNγ under 
conditions of osteoblastic differentiation 
hMSC were plated in 4 cm
2 dishes containing 
growth medium at a density of 4 x 10
4 cells per 
dish. After 48 h, media was replaced with 
growth or osteogenic medium containing either 
IFNγ (Sigma-Aldrich, St. Louis, MO, USA) at 
different concentrations (1, 10 and 100 ng/ml), 
or vehicle. Media was changed every 3 days. 
After 1 wk of treatment, media was aspirated and 
cells were stained for both ALP by using TT-
blue+ (Sigma-Aldrich, St. Louis, MO, USA) and 
mineralization by using Alizarin red (Sigma-
Aldrich, St. Louis, MO, USA). The number of 
ALP positive cells per field was quantified in 10 
different fields per well. Matrix mineralization 
was quantified by extracting the Alizarin red 
staining with 100mM cetypyridinium chloride 
(Sigma, St. Louis, MO, USA) at room 
temperature for 3 h. The absorbance of the 
extracted Alizarin red S staining was measured 
at 570 nm. Data represented are expressed as 
units of Alizarin red per mg of protein in each 
culture normalized to the number of cells per 
well. 
 
IFNγ Knockdown by siRNA 
Knockdown of the IFNγ was obtained by gene 
siRNA in differentiating hMSC as previously 
described [13]. Briefly, hMSC were grown in 
MSCGM containing 10% FCS until 60% 
confluence in 6 well plates. Medium was then 
removed and replaced with serum free MSCGM 
and transfected with 300 nmol of siRNA using 
the siRNA oligo transfection kit (sc-29528, 
Santa Cruz, CA) according to the manufacturer’s 
directions. We used a double stranded siRNA 
oligonucleotide against human IFNγ (sc-39606) 
and a negative control siRNA (sc-37007) from 
Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA). Cells were incubated for 5-8 hrs in serum 
free MSCGM and the medium then replaced 
with osteogenic medium. siRNA transfection 
was repeated every 3 days and cells treated for 
up to 14 days. Specific siRNAs directed against 
human IFNγ was a pool of the following 3 
separate strands: Sense strand (a):5’-
CGAAGAGCAUCCCAGUAAUtt-3’ (position 
616-634); sense strand 
(b):5’CUGUGACUGUCUCACUUAAtt-3’ 
(position 807-826); and sense strand (c):5’-
GCAAGGCUAUGUGAUUACAtt-3’ (position 
849-867) (Figure 2B). The positions of the 
siRNAs strands were obtained through GenBank 
mRNA accession number: NM-000619.2. Their 
specificity was verified in the non-redundant 
human DNA database using a BLAST algorithm 
(accessed through the National Center for 
Biotechnology Information). Control siRNA did 
not lead to any specific degradation of known 
cellular mRNA and was selected because it 
exhibited no cellular toxicity. 
 
Semi-quantitative Real Time-Polymerase 
Chain Reaction (RT-PCR) 
At the time points indicated cells were collected 
and washed twice in phosphate-buffered saline 
(PBS). Poly(A)
+ mRNA was isolated with the 
QuickPrep Micro mRNA purification kit 
according to the manufacturer’s specifications 
(GE Healthcare Bio-Sciences Inc., Baie d’Urfe, 
AC, Canada), dissolved in DEPC treated water 
and subjected to DNAse I treatment. 2 µg of 
poly(A)
+ mRNA was reverse transcribed using 
Qiagen One Step RT-PCR Enzyme Mix (Qiagen, 
Valencia, CA, USA). The resulting cDNA was 
amplified by 35 polymerase chain reaction 
cycles with an annealing temperature of 58°C. 
Oligonucleotide primers for IFNγ amplification 
were obtained from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA). The predicted size of the 
IFNγ product was 545 bp (Figure 2B). Genes 
were randomly selected from the list of genes 
with significant change after the 1st and 3rd wk 
of differentiation (see Additional Information). 
Primers were synthesized by Alpha DNA Inc. 
(Montreal, Quebec). Selected primers for the 1st 
wk included IFN-inducible protein 35 (IFI 
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35)(5´–
CTCTGCTCTGATCACCTTTGATCAC–
3´upstream and 5´–
GCTTCTGGAAGTGGATCTCCAGGA–
3´downstream); Interleukin 10 receptor 
(IL10r)(5´–
GAACCTGACTTTCACAGCTCAGTAC–
3´upstream and 5´–
TCAGGTGCTGTGGAAGAGAATTC–
3´downstream);Growth related oncogene 1 
(GRO1)(5´–
GAACATCCAAAGTGTGAACGTGAAG–
3´upstream and 5´–
ATTTGCTTGGATCCGCCAGCCTCTA–
3´downstream); and importin (5´–
GAGAATTGCAGAATTGGCCTGACCT–
3´upstream and 5´–
CTATGTCTGAGTACTTCATGCCA–
3´downstream). For the third wk, selected 
primers included: Transforming growth factor β 
receptor 2 (TGFBR2) (5´–
TACATCGAAGGAGAGCCATTCGC–
3´upstream and 5´–
TGCAGCACACTCGATATGGACCAG–
3´downstream); LDL receptor related protein 5 
(LRP5)(5´–
GTCGTAGTCGATGGCAATGGCGT–
3´upstream and 5´–
ACGGACTCAGAGACCAACCGCATC–
3´downstream); osteopontin (OPN) (5´–
ACTCTGGTCATCCAGCTGACTCGT–
3´upstream and 5´–
CTCCTAGGCATCACCTGTGCCATA–
3´downstream); osteocalcin (OCN) (5´–
TGGCCGCACTTTGCATCGCTGG–
3´upstream and 5´–
CGATAGGCCTCCTGAAAGCCGATG–
3´downstream); and runt-related transcription 
factor 2 (Runx2) (5´–
TGGCCGCACTTTGCATCGCTGG–
3´upstream and 5´–
CGATAGGCCTCCTGAAAGCCGATG–
3´downstream). 
 
Amplification of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) or β-actin was used as 
controls. The expected sizes of the amplification 
products were between 400 and 800 base pair. 
Amplified products were analyzed by either 
1.5% or 2% agarose gel electrophoresis. The 
signals were quantified by densitometry (Bio-
Rad laboratories, Hercules, CA, USA) and 
normalized according to GAPDH or β-actin 
density. 
 
Western Blot Analysis 
Cells were collected at the times indicated, lysed, 
separated by gel electrophoresis and then 
transferred to a nitrocellulose membrane. After 
blocking, the membrane was incubated overnight 
at 4
oC using an antibody directed against Runx2, 
IFNγ, OCN, IFNγ receptor 1 (IFNγR1) (Santa 
Cruz Antibodies, Santa Cruz, CA, USA), or 
tubulin (Sigma, St. Louis, MO, USA), and the 
bound antibodies were detected with the 
corresponding secondary antibodies conjugated 
with horseradish peroxidase. Blots were 
developed by enhanced chemiluminescence 
using Lumi-GLO reagents (Kirkegaard & Perry, 
Gaithersburg, MD, USA). The signals were 
quantified by densitometry and expression ratios 
were normalized according to tubulin density. 
 
Cell Viability and Proliferation Assays 
To assess whether treatment of differentiating 
hMSC with either IFNγ or IFNγ knockdown had 
an effect on their proliferation and survival, cells 
were plated onto 24-well culture and treated with 
either with IFNγ or IFNγ siRNA as previously 
described. After treatment cells were released by 
0.25% v/v trypsin-ethylenediaminotetraacetic 
acid treatment, and resuspended in 10% FCS-
containing media. After centrifugation (1,000 x g 
for 5 min.) cells were resuspended in 10% v/v 
FCS-containing media mixed with 0.4% w/v 
trypan blue in 1:1 ratio and a viable cell count 
performed using a hemacytometer (nonviable 
cells were stained with trypan blue). 
 
For proliferation analysis, MSC cells were 
seeded at a density of 4 x10
2 cells/well in 96-
well cluster plates (Falcon, Becton-Dickinson, 
NJ, USA). Cells were induced to differentiate 
and treated with either IFNγ or IFNγ siRNA as 
previously described. Cell proliferation was 
quantified by MTS-formazan analysis (CellTiter 
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96® AQueous Cell Proliferation Assay, 
Promega, Madison, WI, USA). Briefly, a stock 
solution of MTS was dissolved in PBS at a 
concentration of 5mg/ml and was added in a 
1:10 ratio (MTS/DMEM) to each well, incubated 
at 37
oC for 2h, and the optical density 
determined at a wavelength of 490 nm on a 
microplate reader model 3550 (Biorad, Hercules, 
CA, USA). In preliminary experiments the 
absorbance was found to be directly proportional 
to the number of cells over a wide range (2 x 10
2 
to 5 x 10
4 cells/well). The percent proliferation 
was defined as [(experimental absorbance - 
blank absorbance)/control absorbance - blank 
absorbance)] x 100, where the control 
absorbance is the optical density obtained for 1 x 
10
4 cells/well (number of cells plated at the start 
of the experiment), and blank absorbance is the 
optical density determined in wells containing 
medium and MTS alone. 
 
Animals 
We purchased IFNγR1
-/- mice (strain name 129-
Ifngr
tm1 on a C57BL/6 background) from 
Jackson Laboratory (Bar Harbor, ME, USA). As 
a control strain we purchased the strain name 
129S1/SvImJ on a C57BL/6 background from 
the same source. Mice were housed in cages in a 
limited access room. Animal husbandry adhered 
to Canadian Council on Animal Care Standards, 
and all protocols were approved by the McGill 
University Health Center Animal Care 
Utilization Committee. 
 
Bone Mass Measurements by Dual Energy X-
ray Absortiometry 
Hip and spine bone mineral density (BMD) were 
measured at 4, 8, and 12 wks using a PIXIMUS 
bone densitometer (PIXIMUS 
TM, GE medical 
systems, Schenectady, NY, USA). A quality 
control phantom was used to calibrate the 
densitometer prior to each experiment. 
 
 
Ex-vivo Cultures of Bone Marrow Cells 
Bone marrow cells were prepared and induced to 
differentiate into osteoblast as previously 
described [14]. Briefly, one side tibiae from 4- 
and 8-wk-old IFNGR
-/- and IFNGR
+/+ mice (n= 
12 per group per time point) were flushed using 
a 21-gauge needle attached to a 10 ml syringe 
filled with Dulbecco’s modified Eagle’s medium 
(DME) (GIBCO BRL, Gaithersburg, MD, USA). 
The bone marrow cells were filtered through a 
cell strainer with a 70-micron nylon mesh (BD 
Bioscience, Bedford, MA, USA) and plated in 
10 cm
2 tissue culture dishes. The cells were 
incubated in growth medium at 37°C with 5% 
humidified CO2 and isolated by their adherence 
to tissue culture plastic. Medium was aspirated 
and replaced with fresh medium every 2 to 3 
days to remove non-adherent cells. The adherent 
MSC were grown to confluency for about 7 days 
and defined as MSC at passage 0, harvested with 
0.25% trypsin and 1 mM EDTA for 5 min at 
37ºC, diluted 1:3 in growth medium, plated and 
grown to confluency for further expansion. After 
2
nd and 3
rd passages, MSC were used for 
subsequent experiments. 
 
To induce differentiation, a total of 10
4 cells 
were diluted in osteogenic medium and plated in 
24 dishes per group, each 4 cm
2. Media was 
aspirated and replaced with fresh osteogenic 
medium every 3 days. At 21 days, medium was 
removed and cultures were fixed in 10% v/v 
formol/saline solution for 5 min. Colony forming 
units-osteoblasts (CFU-OB) were detected by 
Alizarin Red (pH 7.4) staining. The total number 
of CFU-OB per dish was counted 
macroscopically with a flat bed scanner fitted 
with a transparency adapter. 
 
Statistical Methods 
Statistical analysis – All data are expressed as 
mean ± SD of three replicate determinations. 
Unless otherwise stated, all experiments were 
repeated three times.  Statistical analysis was 
performed by one-way ANOVA or Student’s t-
test. A probability value of p < 0.05 was 
considered statistically significant. 
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RESULTS 
 
IFNγ Inducible Genes are upregulated during 
hMSC differentiation into osteoblasts in vitro – 
We exposed hMSC to either growth or 
osteogenic medium for a total of 3 wks. 
Subsequently, we examined 12,000 human genes 
in the array Human Genome U95A (Affymetrix, 
Inc. Santa Clara, CA, USA) to assess gene 
expression during the proliferative (wk 1) and 
mineralization (wk 3) phases of osteoblastic 
differentiation. The scatter plots of gene 
expression levels were determined for each time 
point at wk 1 and wk 3 by averaging mRNA 
expression levels from growth and osteogenic 
media exposed cells plotted in a double-
logarithmic scale (see Supplemental Data). 
Genes identified as differentially expressed 
between growth and osteogenic medium treated 
cells had a minimum of 2.5-fold increase or 
decrease in gene expression. At week one and 
three, a subset of markers of early osteoblast 
differentiation [5, 15-20] as well as markers of 
mature osteoblasts [20-21] were differentially 
expressed in response to osteogenic medium 
(Figure 1). In a set of 103 genes during the 
proliferative phase (wk 1), a predominant 
expression of markers of early osteoblast 
differentiation was found (Figure 1A). 
Furthermore, at wk 3 of differentiation, in a set 
of 104 genes, a strong expression of the markers 
of mature osteoblasts [20-21], including ALP, 
osteopontin, OCN and bone sialoprotein2 (BSP-
2), was found (Figure 1B). In addition, a set of 
genes known as IFNγ inducible genes [22-26] 
displayed striking and transient changes in gene 
expression at wk 1 (Figure 1A), and returned to 
normal at wk 3 (Figure 1B). Finally, to estimate 
the reliability of our microarray results, we 
compared our results with those obtained by RT-
PCR normalized for GAPDH on randomly 
selected genes at each time point (Figure 1, C 
and D). 
 
IFNγ is produced following induction of hMSC 
to the osteoblastic lineage and regulates their 
differentiation in an autocrine manner – After 
identification that IFNγ inducible genes were 
upregulated during early osteoblastogenesis, we 
then assessed the capacity of hMSC to produce 
IFNγ prior to, and following, exposure to 
osteogenic medium. Concentrations of IFNγ 
were almost undetectable in the conditioned 
medium of uncommitted hMSC at wks 1 and 2 
(Figure 2A), but increased significantly in the 
3rd wk, confirming previous reports of IFNγ 
production by confluent MSC [27,28]. In 
contrast, conditioned hMSC exposed to 
osteogenic medium showed a dramatic increase 
of IFNγ production at wk 1, and returned to 
baseline at wk 2 (Figure 2 A) (p< 0.01). 
 
We then assessed the effect of IFNγ blockade on 
the ability of hMSC to differentiate into 
osteoblasts. IFNγ blockade did not affect cell 
survival of proliferation (data no shown). We 
compared hMSC differentiation into osteoblasts 
in cells treated with control siRNA and IFNγ 
siRNA. IFNγ mRNA levels remained stable 
throughout the experiment when treated with 
control siRNA (Figure 2C, left panel). In 
contrast addition of IFNγ siRNA induced a rapid 
and sustained inhibition of IFNγ mRNA for the 
duration of the experiment (Figure 2C, right 
panel). This sustained inhibition was also seen 
with IFNγ protein levels (Figure 2D). IFNγ 
blockade in the presence of osteogenic medium 
resulted in a strong inhibition of differentiation 
as shown prior to (Figure 2E) and after staining 
(Figure 2F) with Alizarin red. 
 
IFNγ induces osteoblastogenesis in a dose 
dependent manner – The expression of IFNγR1 
was significantly increased by exposure of 
hMSC to OM and by treatment with IFNγ as 
compared to GM-treated hMSC (p<0.01) (Figure 
3A and B). This increase occurred early (at week 
1) and was sustained for the duration of the 
experiment (Figure 3B). In addition, when 
hMSC were induced to differentiate with OM no 
significant difference in cell proliferation 
between IFNγ- and vehicle-treated cells was 
found (Figure 3C). We then examined the 
capacity of IFNγ to alter the differentiation of 
hMSC into osteoblasts. IFNγ was added 
simultaneously with OM. At wk 1 post addition 
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of IFNγ to hMSC, a significant dose-dependent 
and early increase of ALP expressing cells was 
observed as compared with untreated 
differentiating cells (76% ± 4 vs. 8% ± 2, 
p<0.01), (Figure 3, D and E). Higher doses of 
IFNγ did not cause further increase in the 
percentage of ALP expressing cells (data no 
shown). Similar results were obtained using 
Alizarin red staining, a measure of the ability of 
osteoblasts to mineralize (Figure 3, E and G). 
Quantification of alizarin red staining showed 
that hMSC treated with IFNγ mineralized earlier 
in a dose dependent manner (p<0.01) (Figure 
3G). Additionally, when hMSC were treated 
with increasing concentrations of IFNγ in growth 
medium alone, no effect on either ALP 
expression or mineralization was observed 
(Figure 3D and F). 
 
Expression of osteogenic transcription factors 
following IFNγ knockdown – We first assessed 
whether the high levels of early osteoblast 
differentiation and mineralization induced by 
IFNγ in OM-treated hMSC were concomitant 
with changes in the expression of Runx2. hMSC 
treated with GM either alone or with IFNγ 
(100ng/ml) expressed low levels of Runx2 at 
wk1,2 and 3 (Figure 4 A and B). As expected 
[8], levels of Runx2 expression progressively 
increased after exposure of hMSC to OM (Figure 
4 A and B). In contrast, addition of IFNγ to the 
OM induced a significant increase in expression 
of Runx2 at wk 1 compared to growth medium 
alone-treated cells. IFNγ-treated cells continued 
to display a strong induction of Runx2 at wk 2 as 
compared to OM alone and decreased at wk3 to 
the same levels observed with OM (Figure 4A 
and B). 
 
We next assessed the effect of IFNγ blockade on 
the expression of Runx2 and OCN. Concomitant 
with lower levels of osteoblast differentiation 
and mineralization, a dramatic decrease in the 
expression of Runx2 and OCN was observed in 
cells treated with IFNγ siRNA as compared to 
control siRNA (Figure 4C and D). 
 
IFNγ Signaling Regulates Osteoblast 
Differentiation in vivo 
We then determined the effect of IFNγ signaling 
on osteoblast differentiation in vivo in a mouse 
model in which the IFNγ receptor had been 
disrupted by homologous recombination, the 
IFNγR1
-/-  model. These animals are normal at 
birth, are fertile, have a normal growth rate and 
body weight, and cannot be differentiated from 
the control IFNγR1
+/+  mice, except for subtle 
changes in the immune system [29,30]. Initially, 
we examined BMD changes in IFNγR1
-/-  mice 
and in the control IFNγR1
+/+  mice. BMD 
measured at the spine and femora indicated that 
IFNγR1
-/-  mice had a significantly lower bone 
mass in the spine (41% reduction) compared to 
IFNγR1
+/+  mice (0.038g/cm
2 ± 0.004 vs. 0.064 
g/cm
2 ± 0.005, p<0.01) and in the femur (31% 
reduction) (0.032g/cm
2 ± 0.005 vs. 0.046 g/cm
2 
± 0.002 vs. p<0.01) (Figure 5A). Subsequently, 
to assess whether, as in our in vitro experiments, 
MSC lose their capacity to differentiate into 
osteoblasts in absence of IFNγ signaling in vivo, 
we cultured bone marrow cells derived from 4- 
and 8-wk-old IFNγR1
-/-  and IFNγR1
+/+  mice in 
osteogenic medium. After 3 wks of treatment, 
the number of CFU-OB derived from IFNγR1
-/- 
mice was significantly lower than the number 
derived from 4-wk-old IFNγR1
+/+ mice (6 ± 2 vs. 
21 ± 5, p<0.01)  and 8-wk-old IFNγR1
+/+  mice 
(12 ± 5 vs. 46 ± 2, p<0.01) (Figure 5, B and C). 
Similarly, bone marrow cells derived from 4- 
and 8- week old IFNγR1
+/+ mice and treated for 
14 days with IFNγ siRNA had a significant 
reduction in the number of CFU-OB as 
compared to bone marrow cells treated with 
control siRNA (data not shown). 
 
DISCUSSION 
 
In this study, we identified a new role for IFNγ 
in MSC committed to differentiate into the 
osteoblastic lineage both in vitro and in vivo. We 
first determined the changes in gene expression 
that take place during the differentiation of 
hMSC into osteoblasts. We demonstrated that in 
addition  to the expression of previously 
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described signaling pathways of osteoblast 
differentiation [5], a strong and transient 
induction of a new signaling pathway, IFNγ 
inducible genes, occurred during the 
proliferative phase of hMSC differentiation. 
 
Among these IFNγ inducible genes, IFI-16 and 
absent in melanoma 2 belong to the IFNγ-
induced nuclear protein family NIH-200, which 
is known to play an important role in cell 
differentiation and embryonic development 
[22,23]. Earlier studies had shown that after 
exposure to IFNγ, IFI-16 and absent in 
melanoma 2 interact with Stat heterodimer and 
are translocated to the nucleus by karyopherin 
where they associate with casein kinase 2 
[23,26], a protein involved in osteogenic 
differentiation of hMSC [21, 26]. Our study also 
demonstrates that karyopherin, also known as 
importin beta 2, is upregulated at the end of the 
proliferative phase. 
 
The pattern of gene expression observed 
therefore supports the coordinated and early 
activation of these IFNγ inducible genes during 
the commitment of hMSC to the osteoblastic 
lineage. The transient nature of IFNγ inducible-
genes expression was striking during the 
proliferative phase (wk 1) and returned to 
baseline during the mineralization phase. These 
changes were suggestive of a potential role of 
IFNγ signaling at the early stage of the 
differentiation process of hMSC into osteoblasts 
and triggered us to investigate the regulation of 
IFNγ during this process. In fact, IFNγ 
production by proliferating and osteoblastic 
stromal cells has been reported earlier [27,28]. 
However, the production of IFNγ by MSC 
undergoing osteogenic differentiation was 
considered as a response to the presence of 
factors released by immune cells into the media 
[27]. 
 
An important finding from our study was the 
novel observation of a sharp and transient 
increase in IFNγ production by hMSC induced to 
differentiate into osteoblasts in the absence of 
either immune cells or their released factors. 
This was concomitant with the transient 
expression of IFN-inducible genes, which 
showed a significantly higher expression in 
hMSC committed to differentiate into osteoblasts 
as compared to non-committed hMSC at week 1. 
It is important to note that this difference in gene 
expression does not imply that IFNγ-responsive 
genes have not been activated in undifferentiated 
(non-committed) hMSC at week 3, but rather 
indicates no significant difference in IFNγ-
responsive genes relative expression between 
OM and GM-treated cells at week 3. Consistent 
with previous reports [27,28], we found that 
hMSC express receptors for IFNγ (IFNγR1) and 
that induction of osteogenic differentiation is 
accompanied by a rapid and sustained increase in 
their expression suggesting a synergistic 
interaction between IFNγR1 expression and the 
autocrine production of its ligand. Addition of 
IFNγ further enhanced this rapid and sustained 
increase of IFNγR1 expression only in the 
presence of osteogenic medium further 
supporting this synergistic interaction. 
Interestingly, IFNγR1 expression was initially 
low in non-osteogenic conditions (GM medium) 
and increased rapidly reaching a maximum at 
week 2 suggesting that the late (delayed) 
autocrine production of IFNγ by hMSC may be 
responsible for this delayed increase in IFNγR1 
expression. Taken together, these findings 
suggest that modulation of IFNγR1
  plays an 
important role for hMSC differentiation and acts 
synergistically with IFNγ in an IFNγ autocrine 
loop to modulate osteoblast differentiation. The 
critical role of this autocrine loop was then 
demonstrated by blocking endogenous IFNγ 
production by siRNA in differentiating hMSC 
and also by inducing the differentiation of MSC, 
obtained from the osteopenic IFNγR1
-/-  mice, 
into the osteoblastic lineage. We expected that 
both approaches used here would block 
endogenous IFNγ production prior to the 
induction with the osteogenic medium. We 
found that absence of IFNγ not only inhibited the 
early peak of IFNγ production by hMSC 
observed at wk 1 in vitro, but also significantly 
inhibited MSC differentiation into osteoblasts at 
wk3, both in vitro and in vivo. This evidence 
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indicates that expression of IFNγ by MSC is an 
important early step during their commitment to 
the osteoblast lineage. 
 
Furthermore, to assess the potential effect of 
exogenous treatment with IFNγ on 
osteoblastogenesis, we next added IFNγ to 
osteogenic medium-treated hMSC committed to 
differentiate into osteoblasts. At week 1, IFNγ 
accelerated hMSC differentiation into 
osteoblasts in a dose-dependent manner only in 
the presence of osteogenic medium, indicating 
that and optimal osteogenic milieu is necessary 
for IFNγ effect to occur. This effect was not 
dependent on cell proliferation, indicating that 
IFNγ stimulates differentiation without affecting 
proliferation in the presence of osteogenic 
medium. 
 
Another important finding in this study was the 
observed changes on Runx2 expression in early 
osteoblastogenesis prior to and following IFNγ 
knockdown. Previous studies have indirectly 
linked IFNγ and Runx2 through the crosstalk 
between Runx2 and Stat1, a transcription factor 
regulated by IFNγ [5, 31-33]. Unphosphorylated 
Stat1 physically interacts with Runx2 to inhibit 
its function [5, 32]. However, a direct link 
between IFNγ and Runx2 in the absence of 
immune cells or immune cells-released factors 
has not been reported. In our study, Runx2 
expression, was strongly inhibited following 
knockdown of endogenous IFNγ production 
supporting a mechanistic link between IFNγ 
signaling and Runx2. Additionally OCN, an 
osteogenic protein downstream of the Runx2-
activated pathway [18], was also inhibited after 
IFNγ knockdown. 
 
Addition of IFNγ to MSC growth medium did 
not show an effect on Runx2 expression over the 
levels seen with growth medium alone. In 
contrast, the strongest induction of Runx2 
occurred at wk1 following addition of IFNγ to 
osteogenic media. This strong induction was 
sustained at wk2 but decreased abruptly at wk3. 
The strong initial increase is consistent with 
Runx2-mediated osteoblastogenesis with IFNγ. 
The mechanism underlying the progressive 
decrease in Runx2 expression at weeks 2 and 3 is 
unclear but could be related to down-regulation 
following completion of the differentiation 
process. Taken together, these results strongly 
suggest that IFNγ signaling is a key regulator of 
hMSC differentiation into osteoblast acting at 
least in part through the Runx2-related pathway. 
Further studies looking at the link between 
Runx2 and IFNγ signaling are required. 
 
The significance of our findings relay in the 
importance that osteimmunology has acquired in 
recent years. Although IFNγ is considered to 
play an important role in bone turnover, it has 
been proposed that its role is predominantly in 
the regulation osteoclastic activity [34]. IFNγ is a 
strong inhibitor of osteoclastogenesis in vitro [7, 
34] but stimulates osteoclastogenesis in vivo 
[35]. A significant lack of knowledge exists 
regarding the role of IFNγ on osteoblastogenesis 
and bone formation both in vitro and in vivo. 
 
Overall, our results suggest that, in addition to its 
reported role on osteoclastogenesis and bone 
resorption [31,34-36], IFNγ may also play an 
important role in osteoblastogenesis and bone 
formation both in vitro and in vivo. In addition, 
our finding that hMSC secrete IFNγ in the 
absence of immune cells and that its inhibition 
by siRNA blocks hMSC differentiation into 
osteoblasts suggest that the autocrine secretion 
of IFNγ by hMSC is an essential step in the early 
commitment of hMSC towards 
osteoblastogenesis  in vitro. Considering the 
importance of the cross talk between the immune 
system and skeletal homeostasis [1,7] our data 
showing an effect of IFNγ on hMSC 
commitment to the osteoblast lineage add yet 
another level to the complexity of IFNγ role in 
bone biology. 
 
In conclusion, our data support the concept of an 
IFNγ autocrine loop as an important early step 
for hMSC commitment to the osteoblast lineage. 
Furthermore, the observation that activation of 
IFNγ signaling further enhances hMSC 
differentiation into osteoblasts indicates that 
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additional studies are necessary to determine its 
overall contribution to skeletal homeostasis. 
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  12
Figure 1. Differentially expressed genes between hMSC exposed to either growth medium or 
osteogenic medium after the 1st and 3rd week of differentiation. (A and B) Bars represent the fold 
change of transcript levels of a particular gene between osteogenic medium (OM) and growth medium 
(GM) treated cells (mean of 2 experiments using biological duplication) (p< 0.01). Abbreviations for 
gene names: IFI-16, interferon-inducible protein; PTHR1, parathyroid hormone receptor 1; human 
PDGFR, human platelet-derived growth factor alpha-receptor; TGFBRII, transforming growth factor, 
beta receptor 11; ALP, alkaline phosphatase; OCN, osteocalcin; OPN, osteopontin; LRP-5, LDL 
receptor related protein 5. (C and D) Randomly selected genes, which showed a significant change in 
the microarray analysis (see supplemental data), were tested by semi-quantitative RT-PCR and their 
level of expression was quantified by densitometry and normalized according to GAPDH density. The 
numbers indicate the fold inductions of gene expression by microarray analysis (Affy) as compared to 
semi-quantitative RT-PCR. 
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Figure 2. Autocrine production of IFNγ and its role on osteogenic differentiation of hMSC 
 
(A) hMSC treated with osteogenic medium (OM) produce high levels of IFNγ during the 1st wk of 
differentiation followed by a drop in production during the 2nd and 3rd wks. In contrast, hMSC treated 
with growth medium (GM) had an increase of IFNγ secretion into the media after the 3rd wk in 
culture. (B, C) mRNA expression of IFNγ following treatment of MSC with IFNγ siRNA or control 
siRNA. (B) Partial IFNγ mRNA structure and schematic representation of the three IFNγ siRNA target 
sequences: a, b, and c. Arrows indicate the direction of PCR. Semi-quantitative IFNγ mRNA 
expression (C) was measured by RT-PCR and β-actin served as an internal control. hMSC transfected 
with control siRNA (C, left panel) or IFNγ siRNA (C, right panel) at day 3 (lane 2), day 6 (lane 3), day 
9 (lane 4) and day 14 (lane 5). Line 1 represents untransfected control. Note the strong and sustained 
inhibition of IFNγ mRNA. 
 
(D) Protein expression of IFNγ after either IFNγ siRNA or control siRNA treatment. MSC were 
treated for 14 days in the presence of osteogenic medium (OM). Treatment with IFNγ siRNA inhibited 
IFNγ levels by about 80% as shown in panel D. β-tubulin expression is shown in the lower panel. The 
relative intensity is presented in the bar graph as a ratio of β-tubulin expression. Results are 
representative of three separate experiments. * represents a significant difference from control siRNA, 
p<0.01. 
 
(E) Phase contrast microscopy of MSC treated with osteogenic medium and IFNγ siRNA (or control 
siRNA) for 14 days, (F) MSC were stained with alizarin red and observed under a light microscope. 
There is a marked reduction of mineralization after IFNγ siRNA treatment of osteogenic 
differentiating hMSC (F). 
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Figure 3. Effect of exogenous addition of IFNγ on osteogenic differentiation of hMSC. 
 
(A,B) Treatment of hMSC with IFNγ both in growth (GM) and osteogenic media (OM) induced 
significantly higher levels of IFNγR1 as compared to vehicle treated hMSC (GM). The levels of 
protein expression were significantly higher in GM-treated hMSC at week 3 as compared with week 1 
closely correlating with the presence of IFNγ in the media (Figure 2A). The levels of expression of 
IFNγR1 were significantly increased in hMSC treated with either OM alone or in the presence of IFNγ. 
* represents a significant difference between week 1 and week 3, p<0.01; ** represents a significant 
difference between week 1 and week 3 in hMSC treated with GM p<0.001. 
 
(C) No significant differences in cell proliferation following treatment with increasing doses of IFNγ 
were noted. 
 
(D-G) At week 1, addition of IFNγ in osteogenic medium-treated hMSC accelerates their osteogenic 
differentiation in a dose dependent manner as shown by alkaline phosphatase staining (D and F) and 
the capacity of the differentiated osteoblasts to mineralize after the first week of treatment with IFNγ 
(E and G). The absorbance of the extracted Alizarin red S staining was measured at 570 nm and 
adjusted to the number of cells (G).  At week 1, alizarin red staining quantification (G) shows a 
significantly higher mineralization in the OM+IFNγ-treated as compared with GM+IFNγ-treated cells. 
Six wells were analyzed per experimental condition. Results are representative of three separate 
experiments. * represents a significant difference from GM, p<0.01. 
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Figure 4. Effect of IFNγ knockdown on expression of osteogenic transcription factors 
 
(A) Osteogenic medium (OM) alone induces progressive expression of Runx2 from wk 1 to wk 
whereas no change overtime was observed with growth medium (GM) containing either IFNγ or 
vehicle alone. Addition of IFNγ to the OM induced a significant increase in expression of Runx2 at wk 
1 compared to both OM- and GM-treated cells, which decreased significantly at wk2 and wk3. The 
blots are representative of at least three separate experiments.  (B) Histogram of relative Runx2 
expression from 3 different experiments from the proliferation phase (week 1) to the mineralization 
phase (week 3). * represents a significant difference from GM either with or without treatment with 
IFNγ vs. OM containing either IFNγ or vehicle, p<0.01; σ represents a significant difference between 
OM+ IFNγ and OM-treated cells, p<0.01; φ represents a significant difference between week 1 and 
week 3 in OM+ IFNγ-treated cells, p<0.01; ψ represents a significant difference between week 2 and 
week 3 in OM-treated cells. 
 
(C) Protein expression of Runx2 and osteocalcin (OCN) after IFNγ siRNA, or control siRNA 
treatment. MSC were treated for 14 days in the presence of osteogenic medium (OM). Treatment with 
IFNγ siRNA inhibited Runx2 and osteocalcin levels by about 80% as shown in panel D. β-tubulin 
expression is shown in the lower panel. (D) The relative intensity to these proteins is presented in the 
bar graph as a ratio of β-tubulin expression. Results are representative of three separate experiments. * 
represents a significant difference from control siRNA, p<0.01. 
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Figure 5. Effect of IFNγ signaling disruption on bone mineral density and MSC differentiation 
into osteoblasts. 
 
(A) Bone mineral density of IFNγR1
-/- and IFNγR1
+/+ mice over time. IFNγR1
-/- mice have a lower 
bone mass as compared to IFNγR1
+/+ mice in both spine and femur at 4, 8 and 12 wks (*p<0.01). (B) 
Formation of CFU-OB in ex-vivo cultures of bone marrow cells from 4- and 8-wk-old IFNγR1
+/+ (left 
panels) and IFNγR1
-/- (right panels). Bone forming nodules (CFU-OB) were much more abundant after 
3 wks of induction of differentiation of bone marrow cells treated with osteogenic medium and derived 
from IFNγR1
+/+ mice compared to IFNγR1
-/- mice. (C) Quantification of CFU-OB. IFNγR1
-/- mice (■) 
show a decreased number of CFU-OB per plate as compared to their IFNγR1
+/+ control mice (□) (* p< 
0.01). 
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